Publications by authors named "Funda D Korkmaz"
Article Synopsis
- Angiogenesis is the formation of new blood vessels, essential for tissue health and involved in conditions like tumor growth and inflammation.
- This study focuses on the compound FDI-6 and its unexplored connection to angiogenesis, particularly its impact on VEGF-B protein expression and interaction with the VEGFR1 protein, crucial for initiating angiogenesis.
- Results indicate FDI-6 has distinct cytotoxic effects on different cell types and regulates VEGF-B expressions, promoting future research into its potential as a therapeutic agent in angiogenesis-related diseases.
Article Synopsis
- - The study investigates the use of memantine, an NMDA receptor blocker, to see if it can inhibit cancer cell activity and offer a chemopreventive effect in 4T1 tumor-bearing mice.
- - 26 female Balb/c mice were divided into three groups to assess tumor volume, immune response, and DNA methylation levels after different dosages of memantine treatment over a 10-day period.
- - Results showed that the high-dose memantine group had significantly reduced tumor volumes, increased IL-6 levels in the spleen, and lower DNA methylation levels compared to the control group, suggesting potential benefits of memantine in cancer management.
Antitumorigenic Effect of Memantine via Interfering Glutamate Metabolism in Mouse 4T1 Breast Tumor Model.
Anticancer Agents Med Chem
January 2022
Background: Repurposing drug is an efficient strategy as the drug discovery process is timeconsuming, laborious and costly. Memantine is already used in Alzheimer's disease to prevent neurons from excess glutamate toxicity. As cancer cells benefit from higher amounts of cellular energetics like glucose and glutamine, we used memantine to interfere with the glutamate metabolism in order to restrict cancer cells' glutamine as a source for their growth.
View Article and Find Full Text PDFObjectives: Lung cancer stands out as the most common cancer type worldwide. The most common genetic alteration detected in adenocarcinoma patients is KRAS. KRAS mutated patients still cannot get benefit from precision medicine approaches and lack a targeted therapy.
View Article and Find Full Text PDF